Research Topics
Genomes and Genes
| Benjamin H LeeSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
JAK2T875N is a novel activating mutation that results in myeloproliferative disease with features of megakaryoblastic leukemia in a murine bone marrow transplantation modelThomas Mercher
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Blood 108:2770-9. 2006..These findings provide new insights into pathways and therapeutic targets that contribute to the pathogenesis of AMKL...- Excessive centrosome abnormalities without ongoing numerical chromosome instability in a Burkitt's lymphomaStefan Duensing
Department of Pathology, Harvard Medical School, Armenise 537, 200 Longwood Avenue, Boston, MA 02115, USA
Mol Cancer 2:30. 2003..Moreover, our results suggest a model in which additional cellular alterations may be required to promote centrosome-related mitotic defects in tumor cells... - FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemiaBenjamin H Lee
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 12:367-80. 2007..This model provides insights into the consequences of constitutive signaling by an oncogenic tyrosine kinase on hematopoietic progenitor quiescence, function, and cell fate... - MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaYana Pikman
Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
PLoS Med 3:e270. 2006.... 
Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia veraGerlinde Wernig
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 13:311-20. 2008....
FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stressZuzana Tothova
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, and Department of Genetics, Harvard Medical School, Boston, MA 02115, USA
Cell 128:325-39. 2007..Thus, FoxO proteins play essential roles in the response to physiologic oxidative stress and thereby mediate quiescence and enhanced survival in the HSC compartment, a function that is required for its long-term regenerative potential...- Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate allelesStefan Fröhling
Division of Hematology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 12:501-13. 2007.... - FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignanciesJing Chen
Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
Oncogene 24:8259-67. 2005..These data indicate that PKC412 may be a useful molecularly targeted therapy for MM associated with overexpression of FGFR3, and perhaps other diseases associated with dysregulation of FGFR3 or related mutants... - FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse modelBenjamin H Lee
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Oncogene 24:7882-92. 2005.... - Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cellsWinnie F Tam
Hematology Division, Brigham and Women s Hospital, Boston, MA 02115, USA
Blood 112:1981-92. 2008..These findings indicate that Id1 is an important target of constitutively activated tyrosine kinases and may be a therapeutic target for leukemias associated with oncogenic tyrosine kinases... - The OTT-MAL fusion oncogene activates RBPJ-mediated transcription and induces acute megakaryoblastic leukemia in a knockin mouse modelThomas Mercher
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
J Clin Invest 119:852-64. 2009.... - Activation of FIP1L1-PDGFRalpha requires disruption of the juxtamembrane domain of PDGFRalpha and is FIP1L1-independentElizabeth H Stover
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 103:8078-83. 2006..These results suggest that disruption of the autoinhibitory JM domain is an alternative, dimerization-independent mechanism by which chimeric tyrosine kinases are constitutively activated and induce leukemogenesis... - Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotypeJoseph D Growney
Division of Hematology and Department of Pathology, Brigham and Women s Hospital, 1 Blackfan Circle, Boston, MA 02115, USA
Blood 106:494-504. 2005.... - The homeobox gene CDX2 is aberrantly expressed in most cases of acute myeloid leukemia and promotes leukemogenesisClaudia Scholl
Division of Hematology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
J Clin Invest 117:1037-48. 2007.... - Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant modelGerlinde Wernig
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Blood 107:4274-81. 2006.... - Constitutively activated FGFR3 mutants signal through PLCgamma-dependent and -independent pathways for hematopoietic transformationJing Chen
Howard Hughes Medical Institute, Harvard Medical Scgool, Boston, MA, USA
Blood 106:328-37. 2005..These data indicate that engagement of multiple signaling pathways, including PLCgamma-dependent and PLCgamma-independent pathways, is required for full hematopoietic transformation by constitutively activated FGFR3 mutants... - Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation modelsMelanie G Cornejo
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Blood 113:2746-54. 2009..These data demonstrate that constitutive JAK3 activation disrupts T-cell homeostasis and induces lymphoproliferative diseases in mice... - K-RasG12D-induced T-cell lymphoblastic lymphoma/leukemias harbor Notch1 mutations and are sensitive to gamma-secretase inhibitorsThomas Kindler
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
Blood 112:3373-82. 2008..These data indicate that patients with T-cell leukemia with K-Ras mutations may benefit from therapies that target the NOTCH pathway alone or in combination with inhibition of the PI3K/AKT/MTOR and RAS/MAPK pathways... - Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITDJennifer L Rocnik
Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Blood 108:1339-45. 2006.... - The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivoElizabeth H Stover
Division of Hematology, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115, USA
Blood 106:3206-13. 2005..In summary, AMN107 can inhibit myeloid proliferation driven by TEL-PDGFRbeta and FIP1L1-PDGFRalpha and may be a useful drug for treatment of patients with myeloproliferative disease who harbor these kinase fusions... - Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesisInga Hofmann
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
Cell Stem Cell 4:559-67. 2009..Furthermore, the Hh pathway may not be a compelling target in certain hematopoietic malignancies... - STAT5 is crucial to maintain leukemic stem cells in acute myelogenous leukemias induced by MOZ-TIF2Winnie F Tam
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA, USA
Cancer Res 73:373-84. 2013..Therefore, targeting aberrantly activated STAT5 or rewired downstream signaling pathways may be a promising therapeutic option... - Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine modelDimple Bansal
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 103:16924-9. 2006..Inasmuch as many human leukemias show dysregulated expression of a spectrum of HOX family members, these collective findings also suggest a central role for CDX4 expression in the genesis of acute leukemia... - MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitorsBrian J P Huntly
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Boston, MA 02115, USA
Cancer Cell 6:587-96. 2004..These data demonstrate that some, but not all, leukemia oncogenes can confer properties of leukemic stem cells to hematopoietic progenitors destined to undergo apoptotic cell death... - PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorderJing Chen
Howard Hughes Medical Institute, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 101:14479-84. 2004..Therefore, PKC412 may be a useful therapy for treatment of human stem cell leukemia-lymphoma syndrome... - PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative diseaseJan Cools
Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 3:459-69. 2003..Our data establish PKC412 as molecularly targeted therapy for HES and other diseases expressing activated PDGFRalpha and demonstrate the potential of alternative kinase inhibitors to overcome resistance in target tyrosine kinases... - The value of Wilms tumor susceptibility gene 1 in cytologic preparations as a marker for malignant mesotheliomaJonathan L Hecht
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA
Cancer 96:105-9. 2002..In assessment of effusion specimens with metastatic carcinoma, nuclear reactivity for WT1 is highly suggestive of an ovary primary tumor..
Research Grants
- Murine models of activated FLT3 receptor tyrosine kinaseBenjamin Lee; Fiscal Year: 2007....